Posted by Michael Wonder on 30 Jul 2020
Imago BioSciences granted access by European Medicines Agency to PRIME scheme for IMG-7289 (bomedemstat) in myelofibrosis
30 July 2020 - Access granted on positive primary analysis of the ongoing Phase 2 trial to evaluate the safety and efficacy of IMG-7289 (bomedemstat) .
Imago BioSciences today announced that the EMA granted access to its PRIME (PRIority MEdicines) scheme for IMG-7289 (bomedemstat), a lysine-specific demethylase-1 inhibitor, for the treatment of intermediate-2 and high-risk patients with myelofibrosis who have become intolerant of, resistant to, or are ineligible for a Janus kinase inhibitor.
IMG-7289 is being evaluated in an open-label Phase 2 clinical trial for the treatment of advanced myelofibrosis, a bone marrow cancer that interferes with the production of blood cells.
